There are reports suggesting an association between the rs4994 polymorphism in the ADRB3 gene encoding the beta-3 adrenergic receptor and OAB risk in females. The injection of botulinum toxin-A into the bladder wall is recommended as a possible treatment for OAB patients in whom first-line therapies have failed. The aim of our study was to analyze the possible association between the ADRB3:rs4994 polymorphism and the patient-perceived response to a single intra-detrusor injection of botulinum toxin-A in Polish women with overactive bladder.
The study group consisted of 115 consecutive female patients with OAB. The response to botulinum toxin-A was evaluated at three months after injection, as absolute or relative reductions in OAB symptoms or in scores from questionnaires ICIQ-OAB (parts A and B) and ICIQ-LUTS-QoL (parts A and B). ADRB3:rs4994 variants were identified by the sequencing of genomic DNA extracted from buccal swabs.
There were no statistically significant differences between ADRB3:rs4994 [T];[T] homozygotes and [T];[C]+[C];[C] subjects for absolute or relative reductions in symptoms or in scores from all four questionnaire parts at three months after the injection of botulinum toxin-A.
Our results do not support the hypothesis that ADRB3:rs4994 polymorphism is associated with the response to the intra-detrusor injection of botulinum toxin-A in Polish females with overactive bladder.
Journal of clinical medicine. 2022 Dec 17*** epublish ***
Sylwester Michał Ciećwież, Klaudyna Lewandowska, Agnieszka Boroń, Jacek Brodowski, Jacek Kociszewski, Jeremy Simon Clark, Andrzej Ciechanowicz
Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University, 71-252 Szczecin, Poland., Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, 70-111 Szczecin, Poland., Department of Primary Health Care, Pomeranian Medical University, 70-204 Szczecin, Poland., Department of Gynecology, Evangelisches Krankenhaus Hagen, 58135 Hagen, Germany.